Anti-PD-l1 and 4-1BB bispecific antibody and use thereof
By designing bispecific antibodies targeting PD-L1 and 4-1BB, the limitations of existing therapies in terms of efficacy and toxicity have been addressed, achieving high affinity binding and immune activation, making them suitable for the treatment of various tumors and viral infections.
WO2026139021A1PCT designated stage Publication Date: 2026-07-02BIO THERA SOLUTIONS LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- BIO THERA SOLUTIONS LTD
- Filing Date
- 2025-12-26
- Publication Date
- 2026-07-02
Smart Images
Figure CN2025145934_02072026_PF_FP_ABST
Abstract
The present invention belongs to the field of biomedicine. Provided are a bispecific antibody and the use thereof. The bispecific antibody contains a first antigen-binding domain targeting PD-L1 and a second antigen-binding domain targeting 4-1BB. The antibody retains the activity of an anti-PD-L1 antibody, achieves a balance between activity and safety, and has an excellent druggability potential.
Need to check novelty before this filing date? Find Prior Art